Natural Course and Response to Interferon of Chronic Hepatitis B Accompanied by Antibody to Hepatitis B E Antigen
Overview
Affiliations
The course of chronic hepatitis B was studied in 30 patients who had antibody to hepatitis e antigen and hepatitis B virus DNA in the serum and hepatitis B core antigen in the liver. Over a 2-year period, no patient experienced a sustained spontaneous remission of disease, and follow-up liver histology revealed worsening of the disease in four patients. After 2 years of observation, 24 patients were allocated randomly to one of two groups: 12 patients served as untreated controls and 12 received recombinant human alpha-interferon-2a in a dose of 9 million units intramuscularly three times weekly for 16 weeks. Patients who remained viremic after 16 weeks received 3 million units three times weekly for an additional 8 weeks. Abnormal amino-transferases and serum hepatitis B virus DNA persisted without appreciable changes in all untreated patients. Hepatitis B virus DNA rapidly became undetectable and serum aminotransferases fell to normal in eight treated patients. After the end of treatment, hepatitis B virus DNA became detectable once again in seven patients, in six of whom a peak of aminotransferases (range: 256 to 850 units per liter) ensued; subsequently, hepatitis B virus DNA disappeared, and serum aminotransferases again fell to normal in two of the seven. Overall, hepatitis B virus DNA was no longer detectable in serum and liver histology improved in three treated patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Wei S, Hu M, Chen H, Xie Q, Wang P, Li H BMC Gastroenterol. 2022; 22(1):387.
PMID: 35978283 PMC: 9387004. DOI: 10.1186/s12876-022-02471-y.
Breakthroughs and challenges in the management of pediatric viral hepatitis.
Nicastro E, Norsa L, Di Giorgio A, Indolfi G, DAntiga L World J Gastroenterol. 2021; 27(20):2474-2494.
PMID: 34092970 PMC: 8160618. DOI: 10.3748/wjg.v27.i20.2474.
Yu Y, Wan P, Cao Y, Zhang W, Chen J, Tan L Sci Rep. 2017; 7(1):1729.
PMID: 28496097 PMC: 5431827. DOI: 10.1038/s41598-017-01773-6.
Sali S, Alavian S, Foster G, Keyvani H, Mehrnoosh L, Mohammadi N Hepat Mon. 2013; 13(7):e8743.
PMID: 24066002 PMC: 3776148. DOI: 10.5812/hepatmon.8743.
Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety.
Lam Y, Yuen M, Seto W, Lai C Curr Hepat Rep. 2011; 10(4):235-243.
PMID: 22131901 PMC: 3210946. DOI: 10.1007/s11901-011-0109-z.